Loomis, Sayles & Company’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $40.3M | Buy |
713,795
+2,024
| +0.3% | +$118K | 0.05% | 126 |
|
|
2025
Q4 | $42.3M | Sell |
711,771
-1,236
| -0.2% | -$67.3K | 0.05% | 120 |
|
|
2025
Q3 | $38.6M | Sell |
713,007
-13,807
| -2% | -$790K | 0.05% | 142 |
|
|
2025
Q2 | $40M | Buy |
726,814
+156,057
| +27% | +$9.19M | 0.05% | 135 |
|
|
2025
Q1 | $40.3M | Buy |
570,757
+329
| +0.1% | +$22.1K | 0.06% | 131 |
|
|
2024
Q4 | $37.5M | Buy |
570,428
+240,684
| +73% | +$16.1M | 0.05% | 158 |
|
|
2024
Q3 | $23.2M | Sell |
329,744
-1,758
| -0.5% | -$147K | 0.03% | 235 |
|
|
2024
Q2 | $27.3M | Buy |
+331,502
| New | +$27.6M | 0.04% | 202 |
|
|
2023
Q4 | – | Sell |
-465
| Closed | -$41K | – | 980 |
|
|
2023
Q3 | $41K | Hold |
465
| – | – | ﹤0.01% | 635 |
|
|
2023
Q2 | $40K | Sell |
465
-121,050
| -100% | -$11.4M | ﹤0.01% | 648 |
|
|
2023
Q1 | $11.8M | Sell |
121,515
-46,607
| -28% | -$4.83M | 0.02% | 308 |
|
|
2022
Q4 | $17.4M | Sell |
168,122
-188,367
| -53% | -$17.7M | 0.03% | 247 |
|
|
2022
Q3 | $30.2M | Sell |
356,489
-25,949
| -7% | -$2.31M | 0.06% | 159 |
|
|
2022
Q2 | $31.7M | Sell |
382,438
-12,733
| -3% | -$1.01M | 0.06% | 158 |
|
|
2022
Q1 | $30.5M | Sell |
395,171
-57,743
| -13% | -$4.83M | 0.04% | 224 |
|
|
2021
Q4 | $40M | Sell |
452,914
-9,843
| -2% | -$812K | 0.05% | 203 |
|
|
2021
Q3 | $35.8M | Buy |
462,757
+2,684
| +0.6% | +$212K | 0.04% | 221 |
|
|
2021
Q2 | $38.4M | Sell |
460,073
-55,826
| -11% | -$4.43M | 0.05% | 211 |
|
|
2021
Q1 | $39M | Sell |
515,899
-3,549
| -0.7% | -$290K | 0.05% | 195 |
|
|
2020
Q4 | $45.5M | Sell |
519,448
-62,440
| -11% | -$4.95M | 0.06% | 145 |
|
|
2020
Q3 | $44.3M | Sell |
581,888
-31,175
| -5% | -$3.15M | 0.06% | 122 |
|
|
2020
Q2 | $75.6M | Sell |
613,063
-31,009
| -5% | -$3.08M | 0.12% | 73 |
|
|
2020
Q1 | $54.4M | Sell |
644,072
-53,362
| -8% | -$4.6M | 0.11% | 71 |
|
|
2019
Q4 | $59M | Sell |
697,434
-131,710
| -16% | -$9.95M | 0.1% | 78 |
|
|
2019
Q3 | $55.9M | Sell |
829,144
-23,931
| -3% | -$1.84M | 0.11% | 80 |
|
|
2019
Q2 | $73.1M | Sell |
853,075
-4,481
| -0.5% | -$383K | 0.14% | 70 |
|
|
2019
Q1 | $76.2M | Buy |
857,556
+10,355
| +1% | +$960K | 0.15% | 65 |
|
|
2018
Q4 | $72.1M | Sell |
847,201
-72,684
| -8% | -$6.91M | 0.17% | 56 |
|
|
2018
Q3 | $89.2M | Sell |
919,885
-21,407
| -2% | -$2.14M | 0.17% | 54 |
|
|
2018
Q2 | $88.7M | Buy |
941,292
+70,654
| +8% | +$6.19M | 0.18% | 53 |
|
|
2018
Q1 | $70.6M | Buy |
+870,638
| New | +$74.7M | 0.15% | 69 |
|
|
2015
Q1 | – | Sell |
-823
| Closed | -$74K | – | 732 |
|
|
2014
Q4 | $74K | Sell |
823
-105
| -11% | -$8.73K | ﹤0.01% | 688 |
|
|
2014
Q3 | $67K | Hold |
928
| – | – | ﹤0.01% | 686 |
|
|
2014
Q2 | $58K | Sell |
928
-14
| -1% | -$846 | ﹤0.01% | 717 |
|
|
2014
Q1 | $64K | Buy |
942
+708
| +303% | +$52.2K | ﹤0.01% | 698 |
|
|
2013
Q4 | $16K | Hold |
234
| – | – | ﹤0.01% | 743 |
|
|
2013
Q3 | $17K | Sell |
234
-29,295
| -99% | -$1.95M | ﹤0.01% | 721 |
|
|
2013
Q2 | $1.65K | Buy |
+29,529
| New | +$1.84M | 0.01% | 578 |
|
Other funds holding BMRN
VCM
VPM
Loomis, Sayles & Company's BMRN Position: Q1 2026 in Review
Loomis, Sayles & Company increased its BioMarin Pharmaceuticals (BMRN) stake by 0.28% in Q1 2026, buying an estimated $118K and bringing the position to 713,795 shares worth $40.3M. The position accounts for 0.05% of the portfolio, ranked #126.
Loomis, Sayles & Company first reported a position in BMRN in Q2 2013 and has held it in 38 quarters since. The position peaked at $89.2M in Q3 2018. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Loomis, Sayles & Company held 713,795 shares of BioMarin Pharmaceuticals worth $40.3M as of Q1 2026.
- Loomis, Sayles & Company bought 2,024 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $118K.
- BioMarin Pharmaceuticals made up 0.05% of Loomis, Sayles & Company's portfolio in Q1 2026, its #126 holding.
- Loomis, Sayles & Company first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 38 quarters since.
- Loomis, Sayles & Company's BioMarin Pharmaceuticals position peaked at $89.2M in Q3 2018.
- 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Loomis, Sayles & Company's 13F filing for Q1 2026, filed 14 May 2026.